PTGX vs VRTX
Protagonist Therapeutics, Inc. vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
PTGX
Protagonist Therapeutics, Inc.
64
Buy
VS
VRTX
Vertex Pharmaceuticals
64
Buy
| Metric | PTGX | VRTX |
|---|
| AI Score |
64
|
64
|
| Price |
$151.99
|
$525.88
|
| P/E Ratio |
121.74×
|
30.58×
|
| ROE |
-21.2%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.9%
|
86.0%
|
| Debt / Equity |
0.01×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
68.1
|
82.2
|
| Beta |
1.794
|
0.305
|
| Expected Upside |
—
|
+0.3%
|
AI Committee View
Current Innellis committee reasoning for PTGX versus VRTX.
The committee scores are tied.
PTGX and VRTX both score 64/100.
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 82 is in overbought territory — Technical